New drug JAB-21822 targets tough KRAS mutation in advanced cancers
NCT ID NCT05002270
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested a new oral drug called JAB-21822, alone or with cetuximab, in 29 adults with advanced solid tumors (like lung or colorectal cancer) that have a specific KRAS G12C mutation. The main goals were to check safety and find the right dose. Participants had already tried at least one standard treatment. The study is now complete, and results will help decide if further testing is worthwhile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JAB-21822 (a KRAS G12C inhibitor) and cetuximab (an EGFR inhibitor)
- What this could lead to
- If successful, this could lead to a new targeted treatment option for people with advanced solid tumors that have a specific KRAS G12C mutation.
- What could go wrong
- This is an early phase 1/2 trial with only 29 participants, so results are preliminary. The drug may not work for everyone, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinc
Phoenix, Arizona, 85054, United States
-
Mayo Clinc
Scottsdale, Arizona, 85259, United States
-
Mayo Clinc
Jacksonville, Florida, 32224, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.